Other languages Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.04 ^USD	-1.18%		+11.01%	-35.30%

Apr. 09	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT
Apr. 09	Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 09
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	Apr. 09
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	Apr. 09
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene	Mar. 25
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial	Mar. 25
Sector Update: Health Care Stocks Mixed Late Afternoon	Dec. 06
Sector Update: Health Care	Dec. 06
Top Midday Gainers	Dec. 06
Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine	Dec. 06
Top Premarket Decliners	Nov. 27
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Top Premarket Gainers	23-10-17
Sector Update: Health Care Stocks Lower Late Afternoon	23-10-02
Sector Update: Health Care Stocks Retreating Monday Afternoon	23-10-02
Syros Pharmaceuticals Names New CEO; to Cut Staff by 35%; Shares Drop	23-10-02
Syros Pharmaceuticals, Inc. Announces Management Changes	23-10-02
Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023	23-10-02
Syros Pharmaceuticals, Inc. Receives Notice from Incyte Corporation to Terminate the Target Discovery, Research Collaboration and Option Agreement	23-08-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Other languages

Filters